BioInvent International AB held a key opinion leader event on May 27, 2026, to discuss ovarian cancer treatments and TNFR2-targeted therapies.
The virtual event featured company executives and external expert Dmitriy Zamarin. Martin Welschof, president and CEO, opened the session and outlined the agenda covering the treatment landscape and company progress.
Ti AI ṣe iroyin Àwòrán tí AI ṣe Ti ṣayẹwo fun ododo
Researchers at McGill University report a drug-based method to temporarily enhance natural killer (NK) cells—an immune cell type—by inhibiting two proteins, improving the cells’ ability to attack several aggressive cancers in preclinical experiments.
Inovio Pharmaceuticals held its first-quarter 2026 earnings call on May 13 to discuss financial results for the period ended March 31 and provide updates on its DNA medicines platform.
Ti AI ṣe iroyin
Caribou Biosciences discussed progress on its off-the-shelf CAR-T therapies during a presentation at the Bank of America Global Healthcare Conference on May 13. Chief executive Rachel Haurwitz highlighted Phase I data for two programs that target lymphoma and multiple myeloma.
A new treatment called Daraxonrasib has shown strong results against advanced pancreatic cancer in a recent clinical trial. The drug targets a genetic mutation long considered impossible to treat effectively.
Ti AI ṣe iroyin
A protein called NFIL3 has been identified as a key factor in reducing the long-term performance of CAR T cells used in cancer treatment. Researchers showed that disabling this protein allows the engineered cells to remain active longer and fight tumors more effectively in laboratory models.